Topic: drug discovery

The sixth H3D symposium brings scientists and pharmaceutical researchers together around chemistry and biology for infectious diseases. The programme covers drug discovery, chemical biology, medicinal and synthetic chemistry, infectious-disease biology and enabling technologies, with scientific talks, posters and networking. It takes place at the Arabella Hotel, Golf and Spa outside Hermanus, South Africa, from 13 to 16 October 2026. Standard delegate registration is open until 10 October 2026. Abstract submission closed on 15 May and early registration closed on 31 July; those actions are no

PharmSci 360 connects experimental, computational and clinical evidence across drug discovery, development and delivery. Researchers will examine in-vitro-to-human translation using PBPK, quantitative systems pharmacology and AI; organ-chip and other human-relevant models; biomarkers and reliable bioanalytical assays; and integrating clinical trials with real-world data. Manufacturing sessions connect process understanding, analytical characterization and digital models with quality and scale-up. Formulation sessions address predictive design, advanced materials, targeted delivery and patient

Research new machine-learning architectures and training approaches for drug discovery. Design experiments, evaluate models and work with engineering and domain experts to scale promising methods into scientific applications. The position calls for original research together with practical implementation and clear communication across disciplines. Applications remain available on the employer’s role page, with no fixed deadline stated.

Research models that connect chemical structures, protein sequences and cellular transcriptomics to predict biological responses. Develop and test scientific hypotheses using large single-cell perturbation datasets, contributing new architectures and evaluations for drug discovery. The employer lists the role as on-site with at least three office days each week. The exact role page currently accepts applications and states no fixed deadline.

FAPESP-supported postdoctoral fellowship in São Paulo investigating malaria drug discovery and cellular signalling. The project studies new molecular targets, GPCR-like receptors and therapeutic strategies against Plasmodium falciparum. One position is advertised under project 2023/07656-0. Applicants should send a CV and cover or motivation letter describing relevant experience to the investigator listed on the official opportunity page by 12 October.

Carnegie Mellon researcher and Abridge co-founder Zachary Lipton discusses where machine learning can help healthcare and why clinical work is harder to automate than software development. The conversation examines medical documentation, decision support, drug discovery, open models and model routing, then turns to academic research, doctoral training and the effects of automation on scientific careers. Hosted by Ravid Shwartz Ziv and Allen Roush. Watch the full conversation on the publisher’s YouTube channel.

Rafael Rosengarten and BioPharmaTrend co-founder Andrii Buvailo discuss how to assess progress in AI-assisted drug discovery. They trace the move from individual computational tasks to connected research workflows and question whether counting AI-associated drug candidates captures the technology’s value. Topics include research productivity, trial design, biomarkers, human expertise and the use of patient-derived data, organoids and other representative biological systems to improve translation. The conversation also considers why AI has become polarising and how specialised models may fit in

This English-language webinar examines advances in organoid research, production, and drug discovery. Hideya Sakaguchi covers the developmental-biology origins of neural organoid research and its potential for drug discovery, followed by a keynote from Thomas Mitchell of The Organoid Company and a live question session.

Tim Wahlberg of CAS speaks with Rafael Rosengarten about the role of curated chemical knowledge in AI-assisted drug discovery. They examine scientific data quality, harmonisation and expert curation, and consider how reliable information can help researchers formulate questions and evaluate answers from large language models.

The event is open to everyone interested in Neuroscience, Cell Biology, Drug Discovery, Disease Modeling, and Bio/Neuroengineering! This meeting is a platform bringing scientists from all over the world together and fostering scientific exchange and collaboration.

The event is open to everyone interested in Neuroscience, Cell Biology, Drug Discovery, Disease Modeling, and Bio/Neuroengineering! This meeting is a platform bringing scientists from all over the world together and fostering scientific exchange and collaboration.

Recent developments in induced pluripotent stem cell (iPSC) technology have enabled easier access to human cells in vitro. With increasing availability of human iPSC-derived neurons, both healthy and disease cell lines, screening compounds for neurodegenerative diseases on human cells can potentially be performed in the earlier stages of drug discovery. To accelerate the functional characterization of iPSC-derived neurons and the effect of compounds, reproducible and relevant results are necessary. In this webinar, the speakers will: Introduce high-resolution functional imaging of human iPSC